Capital Advisors Inc. OK Sells 140,045 Shares of Tilray Brands, Inc. $TLRY

Capital Advisors Inc. OK trimmed its stake in shares of Tilray Brands, Inc. (NASDAQ:TLRY) by 93.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,005 shares of the company’s stock after selling 140,045 shares during the period. Capital Advisors Inc. OK’s holdings in Tilray Brands were worth $90,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Silverlake Wealth Management LLC bought a new stake in Tilray Brands in the 3rd quarter worth approximately $25,000. Oppenheimer & Co. Inc. bought a new position in shares of Tilray Brands during the 3rd quarter valued at $25,000. Unified Investment Management bought a new position in shares of Tilray Brands during the 3rd quarter valued at $26,000. J.W. Cole Advisors Inc. boosted its stake in shares of Tilray Brands by 203.2% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock worth $30,000 after buying an additional 48,177 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Tilray Brands in the 3rd quarter worth $30,000. Institutional investors own 9.35% of the company’s stock.

Wall Street Analysts Forecast Growth

TLRY has been the subject of a number of research reports. Canaccord Genuity Group started coverage on Tilray Brands in a research report on Tuesday, January 27th. They set a “hold” rating for the company. Roth Mkm raised Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Thursday. ATB Cormark Capital Markets cut their price target on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a research note on Thursday. TD Cowen reduced their price target on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday. Finally, Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $11.20.

Tilray Brands News Roundup

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth upgraded Tilray to Buy after Q3 results, citing the company’s improving outlook and execution—this upgrade helped lift sentiment. Tilray rebounds as Roth Capital upgrades to Buy after Q3 results
• Positive Sentiment: Jefferies reiterated a Buy and kept a high $24 price target, highlighting strong cannabis sales and increased visibility into medium‑term results—this signals confidence from a major broker. Tilray Brands’ strong cannabis sales and upbeat outlook keeps Jefferies analysts bullish
• Positive Sentiment: Tilray reported record Q3 revenue (~$207M), 11% organic growth, gross profit expansion (~$55M) and a 73% jump in international cannabis revenue—management reaffirmed FY26 guidance, which supports the constructive narrative. Tilray Brands Delivers Record Q3 Fiscal 2026 Results
• Positive Sentiment: Sector tailwind: the FDA signaled it won’t enforce some CBD rules, which lifted cannabis/CBD names broadly and supports Tilray’s consumer-facing opportunity. Why Tilray and Other Cannabis Stocks Just Had Their Best Week of 2026
• Neutral Sentiment: Zacks and other analysts describe Q3 as mixed—revenue and narrowing losses are positives, but beverage weakness and margin pressure temper the bullish case. Should Tilray Brands Be in Your Portfolio Post Q3 Earnings?
• Neutral Sentiment: Analysis pieces note improving fundamentals but flag negative cash flow and execution/M&A risk—supportive for medium-term upside but caution on near-term volatility. Tilray Brands Is Looking Better
• Negative Sentiment: Tilray missed EPS expectations (loss of $0.24 vs. est. -$0.14), and investors have been wary of margin compression and beverage-segment softness—these factors triggered earlier intraday selling. Earnings and conference call details
• Negative Sentiment: Some analysts trimmed targets/ratings after the print: ATB Cormark cut its target to $9.00 (sector perform) and TD Cowen lowered expectations—mixed analyst action adds selling pressure at current levels. Analyst rating changes TD Cowen lowers expectations

Tilray Brands Trading Up 6.7%

NASDAQ:TLRY opened at $6.55 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. The firm has a market capitalization of $763.14 million, a price-to-earnings ratio of -0.48 and a beta of 2.00. Tilray Brands, Inc. has a one year low of $3.51 and a one year high of $23.20. The business has a fifty day moving average price of $7.32 and a 200-day moving average price of $10.23.

Tilray Brands (NASDAQ:TLRY) last released its earnings results on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10). Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. The company had revenue of $206.73 million for the quarter, compared to analysts’ expectations of $201.35 million. During the same quarter last year, the firm posted ($0.87) earnings per share. Sell-side analysts forecast that Tilray Brands, Inc. will post -0.2 EPS for the current year.

Tilray Brands Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.